This randomized controlled clinical trial will identify the additional benefit of bismuth or metronidazole in proton pump inhibitor-amoxicillin-containing therapy for Helicobacter pylori first-line treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
732
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGEradication rate of Helicobacter pylori
Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value).
Time frame: At least 4 weeks after completion of therapy
Eradication rate of Helicobacter pylori resistant strains
Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic resistant strains were assessed using the E test method.
Time frame: At least 4 weeks after completion of therapy
Eradication rate of Helicobacter pylori susceptible strains
Eradication of Helicobacter pylori was defined as negative result of urea breath test (\<4‰ cut-off value). The antibiotic susceptible strains were assessed using the E test method.
Time frame: At least 4 weeks after completion of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1g tid